Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 577-586
DOI: 10.4103/ijmpo.ijmpo_136_20
Original Article

How I Treat Medulloblastoma in Children

Amita Mahajan
Department of Pediatric Hematology and Oncology, Indraprastha Apollo Hospital, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Medulloblastoma (MB) is the most common malignant tumor of the central nervous system in children with up to a third of these tumors presenting in children under 3 years of age. Its exquisite radio and chemosensitivity renders high cure rates in children in whom optimal resection has been achieved. Optimal surgery followed by radiation alone can cure about half of these children. The addition of chemotherapy has improved the outcomes dramatically and over 70% of children over 3 years of age with optimal resection and no metastasis can expect to be cured. Increasingly, the focus is on limiting the long-term sequelae of treatment. Precise molecular characterization can enable us to identify patients who can achieve optimal outcomes even in the absence of radiation. Insights into disease biology and molecular characterization have led to dramatic changes in our understanding, risk stratification, prognostication, and treatment approach in these children. In India, there is limited access to molecular profiling, making it challenging to apply biology driven approach to treatment in each child with MB. The Indian Society of Neuro-Oncology guidelines and the SIOP PODC adapted treatment recommendations for standard-risk MB based on the current evidence and logistic realities of low-middle income countries are a useful adjunct to guide clinical practice on a day-to-day basis in our setting.

Keywords

Childhood - craniospinal irradiation - medulloblastoma - molecular characterization


Publication History

Received: 05 April 2020

Accepted: 09 August 2020

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC. et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 2012; 123: 465-72
    CrossrefPubMedGoogle Scholar
  • 2 Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F. et al. Risk stratification of childhood medulloblastoma in the molecular era: The current consensus. Acta Neuropathol 2016; 131: 821-31
    CrossrefPubMedGoogle Scholar
  • 3 Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016; 131: 803-20
    CrossrefPubMedGoogle Scholar
  • 4 Gupta T, Sarkar C, Rajshekhar V, Chatterjee S, Shirsat N, Muzumdar D. et al. Indian Society of Neuro-Oncology consensus guidelines for the contemporary management of medulloblastoma. Neurol India 2017; 65: 315-32
    CrossrefPubMedGoogle Scholar
  • 5 Parkes J, Hendricks M, Ssenyonga P, Mugamba J, Molyneux E, Schouten-van Meeteren A. et al. SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatr Blood Cancer 2015; 62: 553-64
    CrossrefPubMedGoogle Scholar
  • 6 Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S. et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: A retrospective integrated clinical and molecular analysis. Lancet Oncol 2016; 17: 484-95
    CrossrefPubMedGoogle Scholar
  • 7 Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J. et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009; 27: 1627-36
    CrossrefPubMedGoogle Scholar
  • 8 Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D. et al. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: A retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol 2018; 19: 1602-16
    CrossrefPubMedGoogle Scholar
  • 9 Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S. et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: A retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 2018; 19: 785-98.8
    CrossrefPubMedGoogle Scholar
  • 10 Das A, Ramaswamy V. Less treatment for Wing less medulloblastoma: Germline data re-emphasize this. Neuro Oncol 2020; 22: 7-9
    CrossrefPubMedGoogle Scholar
  • 11 Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN. et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 2010; 28: 1345-50
    CrossrefPubMedGoogle Scholar
  • 12 Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M. et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 2011; 122: 231-40
    CrossrefPubMedGoogle Scholar
  • 13 Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, Gupta D. et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: A simplified approach. Brain Pathol 2016; 26: 334-43
    CrossrefPubMedGoogle Scholar
  • 14 Iv M, Zhou M, Shpanskaya K, Perreault S, Wang Z, Tranvinh E. et al. MR imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2019; 40: 154-61
    CrossrefPubMedGoogle Scholar
  • 15 Dasgupta A, Gupta T, Pungavkar S, Shirsat N, Epari S, Chinnaswamy G. et al. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: Results from a radiogenomics study of 111 patients. Neuro Oncol 2019; 21: 115-24
    CrossrefPubMedGoogle Scholar
  • 16 Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA. et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123: 473-84
    CrossrefPubMedGoogle Scholar
  • 17 Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK. et al. “Large cell/anaplastic” medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000; 59: 857-65
    CrossrefPubMedGoogle Scholar
  • 18 Huang PI, Lin SC, Lee YY, Ho DM, Guo WY, Chang KP. et al. Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute. Childs Nerv Syst 2017; 33: 1285-94
    CrossrefPubMedGoogle Scholar
  • 19 Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P. Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurgery 1996; 38: 265-71
    CrossrefPubMedGoogle Scholar
  • 20 Fritsch MJ, Doerner L, Kienke S, Mehdorn HM. Hydrocephalus in children with posterior fossa tumors: Role of endoscopic third ventriculostomy. J Neurosurg 2005; 103: 40-2
    Google Scholar
  • 21 Muzumdar D, Deshpande A, Kumar R, Sharma A, Goel N, Dange N. et al. Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients. J Pediatr Neurosci 2011; 6: S78-85
    CrossrefPubMedGoogle Scholar
  • 22 Meyers SP, Wildenhain SL, Chang JK, Bourekas EC, Beattie PF, Korones DN. et al. Postoperative evaluation for disseminated medulloblastoma involving the spine: Contrast-enhance MRI findings, CSF cytologic analysis, timing of disease recurrence, and patient outcomes. AJNR Am J Neurradiol 2000; 21: 1757-65
    Google Scholar
  • 23 Terterov S, Krieger MD, Bowen I, McComb JG. Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, primitive neuroectodermal tumors, and ependymomas. J Neurosurg Pediatr 2010; 6: 131-6
    CrossrefPubMedGoogle Scholar
  • 24 Schreiber JE, Palmer SL, Conklin HM, Mabott DJ, Swain MA, Bonner MJ. et al. Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study. Neuro Oncol 2017; 19: 1673-82
    CrossrefPubMedGoogle Scholar
  • 25 Lanier JC, Abrams AN. Posterior fossa syndrome: Review of the behavioral and emotional aspects in pediatric cancer patients. Cancer 2017; 123: 551-9
    CrossrefPubMedGoogle Scholar
  • 26 Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL. et al. Phase III study of craniospinal irradiation followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-8
    CrossrefPubMedGoogle Scholar
  • 27 Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P. et al. Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 2000; 18: 3004-11
    CrossrefPubMedGoogle Scholar
  • 28 Grosshans DR. Proton therapy for pediatric medulloblastoma. Lancet Oncol 2016; 17: 258-9
    CrossrefPubMedGoogle Scholar
  • 29 Sreeraman R, Indelicato DJ. Proton therapy for the treatment of children with CNS malignancies. CNS Oncol 2014; 3: 149-58
    CrossrefPubMedGoogle Scholar
  • 30 Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A. et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: A children's oncology group phase I/II study. J Clin Oncol 2012; 30: 2648-53
    CrossrefPubMedGoogle Scholar
  • 31 Michels EM, Schouten-Van Meeteren AY, Doz F, Janssens GO, van Dalen EC. Chemotherapy for children with medulloblastoma. Cochrane Database Syst Rev 2015; 1: CD006678
    PubMedGoogle Scholar
  • 32 Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-51
    CrossrefPubMedGoogle Scholar
  • 33 Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ. et al. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: Report from the Children's Oncology Group. Pediatr Blood Cancer 2014; 61: 102-6
    CrossrefPubMedGoogle Scholar
  • 34 Kuhl J, Beck J, Bode U. Delayed radiation therapy after post-operative chemotherapy in children less than 3 years of age 14 with medulloblastoma: Results of the trial HIT-SKK 87 study and preliminary results of the pilot trial HIT-SKK 92. Med Pediatr 15 Oncol 1995; 25 Suppl: 250
    Google Scholar
  • 35 Rutkowski S, Bode U, Dienlein F, Ottensmeier H, Warmuth-Metz M, Sorensen N. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978-86
    CrossrefPubMedGoogle Scholar
  • 36 Rutkowski S. Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 2006; 6: 1211-21
    CrossrefPubMedGoogle Scholar
  • 37 Rutkowski S, Gerber NU, von Hoff K, Gnekow A, Bode U, Graf N. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol 2009; 11: 201-10
    CrossrefPubMedGoogle Scholar
  • 38 Von bueren AO, von Hoff K, petsch T, Gerber NU, Warmuth-Metz M, Deinlein F. et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol 2011; 13: 669-79
    CrossrefPubMedGoogle Scholar
  • 39 Perez-Martinez A, Lassaletta A, Gonzalez-Vincent M, Sevilla J, Diaz MA, Madero L. High dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2005; 71: 33-8
    CrossrefPubMedGoogle Scholar
  • 40 Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-20
    PubMedGoogle Scholar
  • 41 Sung KW, Yoo KH, Cho EJ, Koo HH, Lim DH, Shin HJ. et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48: 408-15
    CrossrefPubMedGoogle Scholar
  • 42 Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E. et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27: 566-71
    CrossrefPubMedGoogle Scholar
  • 43 Robinson GW, Rudneva VA, Buchhalter I, Billups C, Waszak SM, Smith KS. et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): Therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 2018; 19: 768-84
    CrossrefPubMedGoogle Scholar
  • 44 Perreault S, Lober RM, Carret AS, Zhang G, Hershon L, Decarie JC. et al. Surveillance imaging in children with malignant CNS tumors: Low yield of spine MRI. J Neurooncol 2014; 116: 617-23
    CrossrefPubMedGoogle Scholar
  • 45 Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatric Blood Cancer 2010; 54: 649-51
    CrossrefPubMedGoogle Scholar
  • 46 Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R. et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: A report from the HIT-SIOP-PNET4 study. J Neurooncol 2016; 129: 515-24
    CrossrefPubMedGoogle Scholar
  • 47 Bonney PA, Santucci JA, Maurer AJ, Sughrue ME, McNall-Knapp RY, Battiste JD. Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases. J Clin Neurosci 2016; 26: 161-3
    CrossrefPubMedGoogle Scholar
  • 48 Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T. et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012; 59: 511-7
    CrossrefPubMedGoogle Scholar
  • 49 Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E. et al. Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. Oncotarget 2018; 9: 10175-83
    CrossrefPubMedGoogle Scholar
  • 50 Lin J, Zheng Y, Chen K, Huang Z, Wu X, Zhang N. Inhibition of FOXMI by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy. Oncol Rep 2013; 30: 1739-44
    CrossrefPubMedGoogle Scholar